SRL Ranbaxy to Market DiaGenic's Breast Cancer Dx in India

May 23, 2008

NEW YORK (GenomeWeb News) – Norwegian diagnostics developer DiaGenic said today that it has signed up SRL Ranbaxy to market its genomic breast cancer test in India.

SRL Ranbaxy is a clinical reference pathology lab network with 40 labs and around 750 collection centers in India.

DiaGenic said it conducted a study of its blood-based gene expression test in India that showed it was not affected by variations in ethnicity or by the menopausal state of the patient.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Closely Intertwined

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Little From Here and There

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

This Week in Science

In Science this week: in vitro generation of human reproductive cells, and more.

All the Arms for Hugging

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.

Main menu